Treatment Strategies for a Rapidly Evolving Landscape in Chronic Lymphocytic Leukemia Management

Scientists address treatment duration and sequence considerations and discuss current targeted treatment dilemmas of chronic lymphocytic leukemia, where they review B cell lymphoma 2 inhibitors and Bruton’s tyrosine kinase in a fixed duration and continuous treatment manner.
[Hematological Oncology]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Quantification of Cell-Free DNA for the Analysis of CD19-CAR-T Cells during Lymphoma Treatment

Cell-free DNA isolated from 74 blood samples of 12 patients during lymphoma treatment with the anti-CD19 CAR-T cell product axicabtagene ciloleucel were analyzed.
[Molecular Therapy-Methods & Clinical Development]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Muscle-Specific Programmed Cell Death 5 Deletion Attenuates Cardiac Aging

Researchers revealed that programmed cell death 5 (Pdcd5) deficiency attenuated cardiac aging by reducing cellular senescence and apoptosis, and increasing Parkin-mediated mitophagy, likely through p53.
[International Journal of Cardiology]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Moracin D Induces Apoptosis in Prostate Cancer Cells via Activation of PPAR Gamma/PKC Delta and Inhibition of PKC Alpha

Researchers explored the apoptotic mechanism of Moracin D in prostate cancer cells in association with peroxisome proliferator-activated receptor gamma (PPAR-γ)-related signaling involved in lipid metabolism.
[Phytotherapy Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Precigen Announces Clearance of IND to Initiate Phase I/Ib Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors

Precigen, Inc. announced that the US FDA has cleared the Investigational New Drug (IND) application to initiate the Phase I/Ib clinical trial of PRGN-3007 in advanced receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) hematological and solid tumors.
[Precigen, Inc.]
[zotpress userid=’7992332′ items=’DDDDDDDD’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Whole-Genome Landscape of Adult T Cell Leukemia/Lymphoma

The authors performed whole-genome sequencing of 150 adult T cell leukemia/lymphoma (ATL) cases and revealed the overarching landscape of genetic alterations in ATL.
[Blood]
[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

CD200 Expression in Hematopoietic Neoplasms: Beyond a Marker for Diagnosis of B Cell Neoplasms

Investigators review CD200 expression and its role in the immune evasion of non-B cell hematopoietic neoplasms and conclude that CD200 appears to be involved in the immune evasion of malignant cells, which could affect the survival of patients.
[Critical Reviews in Oncology Hematology]
[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Lymphocyte Access to Lymphoma Is Impaired by High Endothelial Venule Regression

Scientists reported that lymphoma caused severe high endothelial venules (HEVs) regression in mouse models that phenocopied aggressive human B cell lymphomas, and that HEV dedifferentiation occurred as a consequence of a disrupted lymph-carrying conduit system.
[Cell Reports]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

B Cell to T Cell Ratio as a Novel Indicator in Flow Cytometry in the Diagnosis of Thyroid Lymphoma

Investigators retrospectively analyzed 26 patients with primary thyroid lymphomas and 16 patients with benign lymphoproliferative lesions.
[Endocrine Journal]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Long-Term Outcome of Hyper-CVAD-R for Burkitt Leukemia/Lymphoma and High-Grade B Cell Lymphoma: Focus on CNS Relapse

Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, focusing on its efficacy to prevent CNS relapse.
[Blood Advances]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Hematopoietic Stem Cell Transplantation for Infants with High-Risk KMT2A Gene–Rearranged Acute Lymphoblastic Leukemia

43 patients received hematopoietic stem cell transplantation (HSCT) in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival of 56.8% and overall survival of 80.2% were accomplished.
[Blood Advances]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share
Share